Recently, venetoclax demonstrated impressive clinical activity in combination with BTK inhibitor ibrutinib in a phase II study involving previously untreated high-risk and older patients with CLL [16]: 92% of the patients had unmutated IgHV, TP53 aberration, or chromosome 11q deletion. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.